Previous close | 8.53 |
Open | 8.76 |
Bid | 8.79 x 100 |
Ask | 8.83 x 300 |
Day's range | 8.61 - 8.92 |
52-week range | 6.06 - 14.34 |
Volume | |
Avg. volume | 658,990 |
Market cap | 479.161M |
Beta (5Y monthly) | 0.95 |
PE ratio (TTM) | 2.97 |
EPS (TTM) | 2.97 |
Earnings date | 07 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 17.78 |
Agios (AGIO) reports mixed earnings results for first-quarter 2024. Though sales miss the mark, revenues from its sole marketed drug, Pyrukynd, rise sequentially and on a yearly basis.
Jazz's (JAZZ) first-quarter earnings and sales miss the mark. The company reaffirms its guidance for full-year 2024.
Spotlight on new, second-generation, TRACER™-derived AAV capsids; translatability as evidenced by cross-species and receptor data; and activity against therapeutic targets in Alzheimer’s disease and ALSLEXINGTON, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that it will present a broad set of data related to its TRACER™ capsid discovery platform and TRACER-driven gene th